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Background: Sirtuin 1 (Sirt1) is a nuclear enzyme from the class III histone deacetylases that modulates gene
expression and is involved in bone and cartilage remodeling. The goal of our study was to evaluate Sirt1 activity in
peripheral blood mononuclear cells in patients with osteoarthritis in comparison with control patients, and to
determine the relationship between Sirt1 activity and production of TNFα, IL-6 and IL-8 by peripheral blood
mononuclear cells after ex vivo treatment with resveratrol, a Sirt1 activator.
Results: A prospective study was performed to compare the activity of Sirt1 in patients with primary osteoarthritis
of the knee (American College of Rheumatology criteria) with its activity in controls. Peripheral blood mononuclear
cells were isolated from peripheral blood, and Sirt1 activity evaluated from cytoplasmic and nuclear compartments
using a fluorometric assay. Culture supernatant levels of TNFα, IL-6, and IL-8 were quantified before and after
resveratrol ex vivo treatment. Nineteen patients with symptomatic knee osteoarthritis (age 64 ±9 years) and 18
controls (age 54 ±13 years) were included. No differences were found in cytoplasmic or nuclear Sirt1 activity
between patients and controls. After resveratrol treatment, no changes in TNFα or IL-8 levels were found, but a
significant dose-dependent increase in IL-6 levels was demonstrated in patients with osteoarthritis, but not controls.
Sirt1 activity did not correlate with clinical activity (Lequesne’s index) or inflammation (erythrocyte sedimentation
rate, C-reactive protein).
Conclusion: Sirt1 activity (cytoplasmic and nuclear) from peripheral blood mononuclear cells did not differ
between patients with osteoarthritis and controls. Ex vivo treatment of peripheral blood mononuclear cells with
resveratrol was associated with a dose-dependent increase in IL-6 levels only in patients with osteoarthritis.
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Osteoarthritis (OA) is a common chronic age-related
disease involving cartilage but also synovial membrane
and subchondral bone. It has major functional and
socioeconomic impacts. OA is a polygenic disease [1],
but epigenetic effects are important mediators of OA
biology [2], including DNA methylation and histone* Correspondence: dwendling@chu-besancon.fr; georges.herbein@univ-
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reproduction in any medium, provided the ormodifications. Among histone modifiers, two major
classes are recognized; histone acetyl transferases and
histone deacetylases (HDAC), with opposite effects [3].
HDACs are divided into four classes. Sirtuins belong to
the class III HDACs. Seven types of sirtuins are known,
with different molecular targets. Sirtuin 1 (Sirt1) is the
most studied of the sirtuins with p53, NF-κB and
PGC1α among others as targets. Sirt1 modulates the
expression of genes involved in the regulation of various
biological processes (cell survival, apoptosis, gluconeo-
genesis, adipogenesis, lipolysis), and local and systemic
inflammation, as well as in bone and cartilage remode-
ling [4,5]. In the cartilage, Sirt1 modulates chondrocyteral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Correlation between nuclear and cytoplasmic Sirt1 activity in patients with osteoarthritis (R2 = 0.948).
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chondrocytes [8], and thus may be implicated in the
pathogenesis of OA [9]. This ‘protective’ role of Sirt1 is
reduced by proinflammatory cytokines such as TNFα,
leading to inactivation of Sirt1 in human osteoarthritic
chondrocytes [10]. Sirt1 may be activated by several
compounds [11], including resveratrol [3]. Activation of
Sirt1 by resveratrol has been demonstrated in articular
chondrocytes [12], and resveratrol may have a positive ef-
fect on cartilage protection and apoptosis inhibition [13].
The hypothesis was that Sirt1 activity is reduced in
patients with knee OA compared with healthy controls.
This hypothesis was tested exploring an accessible body
compartment, namely peripheral blood.
The main objective of the study was to evaluate nuclear
and cytoplasmic Sirt1 activity in peripheral blood mono-
nuclear cells (PBMCs) in patients with knee OA in com-
parison to control patients, via venous blood aspiration.
The secondary objectives were to analyze the relationship
between Sirt1 activity and production of mediators of in-
flammation and cytokines (TNFα, IL-6, IL-8) by the cells
after ex vivo treatment with a sirtuin activator, resveratrol.
Results
Nineteen patients with symptomatic primary knee OA
(age 64 ±9 years; mean Lequesne’s index: 8.4; grade II or
III of the Kellgren-Lawrence classification) and 18 con-









Control 382,825 ± 191,023 352,907 ± 195,317 2.6 ± 1.7
Patients 348,713 ± 216,232 316,314 ± 217,313 14.6 ± 11.0
P 0.5 0.8 0.0002were found between patients and controls in cytoplasmic
(P = 0.8) or nuclear (P = 0.5) Sirt1 activity (Table 1).
There was no correlation between Sirt1 activity (nuclear
and cytoplasmic) and biologic inflammation (erythrocyte
sedimentation rate, C-reactive protein). Sirt1 activity did
not correlate with clinical activity assessed by Lequesne’s
index (P = 0.8).
We found a correlation between cytoplasmic and nuclear
Sirt1 activity in both populations (patients with OA and
controls; R2 = 0.948) (Figure 1). Sirt1 activity (nuclear and
cytoplasmic) was correlated to baseline IL-6 (P = 0.002)
and baseline TNFα (P = 0.004) but not with IL-8 (P = 0.74)
(Figure 2 and data not shown). In agreement with the up-
regulation of both Sirt1 protein expression and Sirt1
activity by resveratrol in several cell types [14,15], we
observed a similar increase of both Sirt1 protein expression
and activity in PBMCs isolated from healthy donors
(buffy coats) and treated with resveratrol (Figure 3).
After resveratrol treatment, no changes in TNFα or IL-8
levels were found, but a significant dose-dependent
increase in IL-6 levels in the supernatants of PBMCs
cultured for 48 h was demonstrated in patients with OA
(P = 0.02; Figure 4), but not in controls.
Discussion
The purpose of this study was to evaluate Sirt1 activity in
cells from the peripheral blood compartment, which is









3.0 ± 14.5 29.0 ±
27.2
8.6 ± 5.0 1,083.3 ±
771.6
4.5 ± 2.7 23.7 ±
21.4
5.1 ± 3.6 1,148.7 ±
2,173
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Figure 2 Correlation between Sirt1 activity (nuclear and cytoplasmic) and baseline IL-6 and TNFα in controls and patients
with osteoarthritis.
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from peripheral blood is feasible, allowing an accessible
cell subset for investigation. Moreover, this study demon-
strates that Sirt1 activity is present, not only in the nuclear
compartment but also in the cytoplasmic one, and both
are correlated. Although the literature has previously
shown mainly the nuclear activity of Sirt1 [3], at least two
different mechanisms could account for its biologicalaction. Sirt1 preferentially deacetylates lysine 9 of histone
H3 and lysine 16 of histone H4 [16]. Additionally, Sirt1
interacts directly with the p65 subunit of NF-κB, leading
to deacetylation at lysine 310, culminating in decreased
NF-κB-associated transcription [17]. Sirt1 deacetylates ly-
sine 310 of RelA/p65 without affecting the acetylation
status of other lysine residues [17]. Following resveratrol
treatment, the localization of both Sirt1 and RelA/p65
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Figure 3 Effect of resveratrol on sirtuin 1 activity and expression in healthy controls. (a) Enhanced Sirt1 protein expression and (b) Sirt1
activity in peripheral blood mononuclear cells of healthy controls treated with resveratrol for 48 hours (at 1 μM and 5 μM for western blot and at
5 μM for cytoplasmic Sirt1 activity). BC, buffy coat; TBP, TATA-binding protein.
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tively repress gene expression by deacetylating RelA/
p65 directly on chromatin [16]. In the case of NF-κB,
the heterodimer composed of RelA/p65 and p50 pro-
teins interacts also with HDAC1, 2 and 3 enzymes, ma-
king the regulation of NF-κB-dependent genes even
more complex [18]. Recently, the cathepsin B-mediated
cleavage of Sirt1 by TNFα has been reported [10].Figure 4 Concentration of IL-6 in supernatants of peripheral
blood mononuclear cells isolated from patients with
osteoarthritis and treated ex vivo by resveratrol at 1 μM and 5
μM (P = 0.02).Interestingly, other proinflammatory cytokines participating
in arthritis, including IL-6, have been reported to activate
cathepsin B and therefore could also trigger the cleavage of
Sirt1 [19].
It has been demonstrated that Sirt1 regulates apoptosis-
and cartilage-specific gene expression in human chon-
drocytes and mouse models [20]. Mice without Sirt1
activity are characterized by reduced levels of type II
collagen, aggrecan, glycosaminoglycan, and elevated levels
of matrix metalloproteinases 8, 9 and 13 in the cartilage,
and elevated chondrocyte apoptosis. Normal cartilage
homeostasis requires enzymatically active Sirt1 protein. Im-
paired Sirt1 activity may favor the development of OA.
An impairment of Sirt1 activity was hypothesized in
patients with OA patients, however no difference was
found between patients with OA and controls in regard
to nuclear and cytoplasmic Sirt1 activity. The signifi-
cantly younger age of the controls does not explain this
result, since Sirt1 activity is supposed to decrease with
age. Nevertheless, several other factors including dia-
betes and obesity have been reported to modulate Sirt1
activity [21]. No correlations with erythrocyte sedimen-
tation rate or C-reactive protein were found in our
study, but we found a correlation between Sirt1 and
TNFα and IL-6. Moreover, after resveratrol treatment, a
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PBMCs was found in patients with OA only, without a
change in TNFα levels. Resveratrol enhances the
deacetylase enzymatic activity of Sirt1 [22]. We ob-
served that resveratrol at 1 μM and 5 μM increased the
expression of Sirt1 protein in PBMCs isolated from
buffy coats from healthy donors using western blotting
(Figure 3a). Additionally, the activity of Sirt1 was
increased in PBMCs treated with 5 μM resveratrol
(Figure 3b). In agreement with our data, other studies
report the up-regulation of Sirt1 expression and Sirt1
activity in primary human endothelial cells or human
HepG2 hepatocytes treated with 10 μM resveratrol
[14,22]. Resveratrol at 50 nM inhibits TNFα-induced in-
flammation measured by matrix metalloproteinase-9 ex-
pression in 3T3/NIH cells [15]. Altogether, our data and
those of others indicate a biological effect of resveratrol
at concentrations used in our study (1 to 5 μM).
Recent reports indicate that Sirt1 can stimulate pro-
inflammatory cytokine production [23,24]. In agreement
with increased IL-6 production in response to resveratrol
treatment in PBMCs, HDAC inhibitors inhibit IL-6 release
by bone marrow-derived macrophages exposed to micro-
bial products such as lipopolysaccharides (LPS) and heat-
killed Escherichia coli and Staphylococcus aureus [25,26].
Sirtuin inhibition decreases the production of TNFα, IL-6
and regulated upon activation normal T cell expressed
and secreted (RANTES) in LPS-stimulated macrophages
[23], suggesting that sirtuin activation may favor pro-
inflammatory cytokine production by activated macro-
phages. In agreement with this hypothesis, inhibition of
Sirt1 enzymatic activity reduces LPS-induced levels of
TNFα in monocytes of patients with rheumatoid arthritis
[24]. By contrast, other studies indicate that resveratrol in-
hibits TNFα-induced inflammation via Sirt1 [15], and sup-
presses expression of TNFα, IL-6 and IL-8 [27]. Sirt1
deacetylates the p65 subunit of NF-κB at lysine 310,
attenuating NF-κB transcriptional activation, and thereby
could decrease proinflammatory cytokine production.
Altogether, Sirt1 activity and subsequent proinflammatory
cytokine production may depend on the cell type involved
(monocytes or macrophages, or PBMCs in peripheral
blood compartment versus cells of the cartilage tissue)
and on the activation state of the cell type studied
(unstimulated cells versus LPS-activated cells).
Some findings of our study deserve to be highlighted.
We were able to measure Sirt1 activity in the cytoplasmic
compartment, and found a correlation with nuclear Sirt-1
activity. This demonstrates that Sirt1 activity may be
assessed in PBMCs, allowing more easy access than carti-
lage tissue in humans, and thus could favor repetitive and
sequential evaluations of treatments in the future. Ad-
ditionally, because Sirt1 is involved in cartilage biology, it
could be a major target for future therapies [28].Conclusion
Sirt1 activity (cytoplasmic and nuclear) from PBMCs was
not different between patients with OA and controls.
Nevertheless, ex vivo treatment of PBMCs with resvera-
trol, a Sirt1 activator, was associated with increased IL-6
levels in a dose-dependent manner only in the patients
with OA, suggesting that IL-6 expression could be speci-
fically regulated via Sirt1 in OA. Importantly, Sirt1 activity
may be assessed in PBMCs, in the nuclear as well as in the
cytoplasmic compartment.
Methods
A prospective and comparative monocentric study was
performed to compare the activity of Sirt1 in patients
with OA and controls, after written informed consent.
The protocol was approved by the local ethics commit-
tee (Comité de Protection des Personnes-Est 2). Inclu-
sion criteria were: patients aged 18 to 80 years, with
symptomatic primary knee OA defined according to the
American College of Rheumatology criteria, with radio-
logical grading (Kellgren-Lawrence classification over I).
Exclusion criteria were: immunosuppressive drugs, dia-
betes or neurodegenerative disease. The control group
consisted of healthy volunteers. Symptoms were quanti-
fied with Lequesne’s algofunctional index for knee OA.
PBMCs were isolated by Ficoll gradient centrifugation.
Blood from a patient or a healthy donor was diluted with
equal amounts of PBS, overlaid on Ficoll medium
(Eurobio, Les Ulis, France) and centrifuged at 900 X g
for 30 min at 25°C. The PBMC band was removed and
washed twice with PBS. Cell count was determined by
Malassez cytometry (Poly Labo, Strasbourg, France), and
cells were resuspended in serum-free Roswell Park
Memorial Institute medium 1640.
Isolation of nuclear and cytoplasmic extracts was per-
formed as follows. After isolation, PBMCs were harvested
and washed with wash buffer (10 mM HEPES (pH 7.6),
10 mM KCl, 2 mM MgCl2, 1 mM EDTA). Cell pellets
were then incubated on ice with cytoplasmic isolation
buffer (10 mM HEPES (pH 7.6), 10 mM KCl, 2 mM
MgCl2, 1 mM EDTA, 0.02% Nonidet P-40). Cytoplasmic
extracts were collected by centrifugation, and the nu-
clear pellets were washed twice in wash buffer, spun,
and incubated for 15 min on ice with nuclear isolation
buffer (20 mM HEPES (pH 7.6), 420 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 25% glycerol). Supernatants
containing nuclear extracts were collected by centrifu-
gation and stored at -80°C. Protease inhibitors (1 mM
DTT, 1 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml leupeptin,
1 μg/ml pepstatin) were added to all solutions. Protein
concentration in nuclear and cytoplasmic extracts was de-
termined by the Bradford method using a Bio-Photometer
(Eppendorf, Hamburg, Germany). The purity of cytoplas-
mic and nuclear extracts was further confirmed by the
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marker, and TATA-binding protein, a nuclear marker,
using western-blotting (data not shown).
For western blot analysis, 10 μg of cellular extracts were
resolved on 10% SDS-PAGE using a Mini-PROTEAN 3
Cell (Bio-Rad Laboratories, Hercules, CA, USA). The
proteins were electrotransferred onto a polyvinylidene
difluoridemembrane (Amersham Biosciences, Saclay,
France) using Mini Trans-Blot Electrophoretic Transfer
Cell (Bio-Rad Laboratories). The membranes were
probed with primary antibodies followed by horseradish
peroxidase-conjugated secondary immunoglobulin raised
against the appropriate species; bands were detected
using the ECL Plus kit (Amersham Biosciences). The pri-
mary antibodies used for western blot are as follows:
rabbit anti-Sirt1 antibody (Cell Signaling Technology,
Beverly, MA, USA); and mouse anti-β-actin antibody and
mouse anti-TATA-binding protein antibody (Sigma-Al-
drich, St. Louis, MO, USA). Horseradish peroxidase-
conjugated secondary antibodies goat anti-rabbit (Santa
Cruz Biotechnology Inc, Santa Cruz, CA, USA) and
rabbit anti-mouse (DakoCytomation, Trappes, France)
were used.
Sirt1 activity was evaluated from cytoplasmic and nuclear
compartments using a fluorometric assay (SIRT1 fluorimet-
ric kit, BML-AK-555; Enzo Life Sciences, Villeurbanne,
France) at the 15-min point. PBMC culture supernatant
levels of TNFα, IL-6 and IL-8 were quantified at 48
hours without and after resveratrol (1 μM and 5 μM)
ex vivo treatment, with commercial kits (Quantikine
Kits, R&D Systems, Minneapolis, MN, USA), according
to the manufacturer’s recommendations. Statistical ana-
lysis was carried out using Wilcoxon and t tests with
significance set at P <0.05.
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